Why Technical Training Advisors in Kentucky are a Primary Focus for Pandemic Recovery Funds

 

One of the more significant side effects of the pandemic on K-12 education in the U.S. was the decreased participation in technical training advisors, or Career and Technical Student Organization (CTSO) advisors. Robin Linton, the CTSO Director for the state of Kentucky, said CTSO involvement fell, at the local and state level, by close to 80% during the pandemic.

This decrease is concerning because CTSOs flourish best as an instructional tool when integrated into a Career and Technical Education curriculum by trained, dedicated, enthusiastic educators.

Some good news finds its way to increase those sagging technical training advisor participation numbers. The Kentucky Department of Education’s approved Elementary and Secondary Emergency Relief Plan (ESSER) allocated $45,000 to support CTSO training. This past fall, more than 215 Kentucky teachers participated in training for new CTSO advisers.

Ron J. Stefanski, host of MarketScale’s “DisruptED,” finds Kentucky’s decision to allocate ESSER funds inspiring and fascinating because the state often puts an educational priority on college preparedness and not enough focus on career readiness.

Ron’s Thoughts

“Recently, Kentucky announced that it’s going to be using its ESSER funds, its COVID recovery funds, to fund training and support for career and tech advisors for students.

What do I think of this? I think this is an incredibly fascinating development. Why do I say that? Because for years we have focused on college readiness oftentimes I feel at the expense of career readiness. And when you look at all the alternative paths now available for students to pursue along an educational pathway that doesn’t move from point A to point B, but may take side ramps to an apprenticeship, to a certificate program, and then back again to college, I think it’s really important to have people who can help students sort that out. So I’m interested to see what transpires in Kentucky.”

Article written by James Kent.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More